Stay updated with breaking news from Alkindi Sprinkle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company anticipates 10-month review for potential approval in Q1 2025 - - Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales…
- Company anticipates 10-month review for potential approval in Q1 2025 -
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call Transcript November 9, 2023 Eton Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.1. Operator: Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company’s […]
Eton Pharmaceuticals' Alkindi Sprinkle is their lead orphan product, addressing a $100M opportunity. Click here to read why ETON stock is a Buy.
What is ahead for Eton Pharmaceuticals, an intriguing small cap concern? Click here for a full investment analysis of ETON stock.